Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer

Cancer Gene Therapy

Volumn 10, Issue 1, 2003, Pages 57-63

  Lee, Choon Taek ^a   Park, Kyung Ho ^a   Adachi, Yasushi ^b   Seol, Ja Young ^a   Yoo, Chul Gyu ^a   Kim, Young Whan ^a   Han, Sung Koo ^a   Shim, Young Soo ^a   Coffee, Keith ^b   Dikov, Mikhail M ^b   Carbone, David P ^b  

^a Seoul National University Hospital   (South Korea)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Adenovirus IGF IR dn; Dominant negative inhibition; IGF IR; Lung cancer

Indexed keywords

AMINO ACID; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECEPTOR; RECOMBINANT DNA; SOMATOMEDIN C RECEPTOR;

ADENOVIRUS; ALPHA CHAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; CELL LINE; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SECRETION; SOLUBILITY; STOP CODON; TUMOR XENOGRAFT; VIRUS RECOMBINANT;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADENOVIRIDAE; ANIMALS; CARCINOMA, LARGE CELL; CELL DIVISION; COLONY-FORMING UNITS ASSAY; FEMALE; GENE THERAPY; GENES, DOMINANT; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; SEQUENCE DELETION; THYMIDINE; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 0037277323     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700524     Document Type: Article

References (31)

1. Baserga R. Oncogenes and the strategy of growth factor. Cell. 1994;79:927-930.
2. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5:2503-2512.
3. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253:1-6.
4. Baserga R. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332:F105-F126.
5. Resnikoff M, Sell C, Rubini M, et al. Rat glioblastoma cells expressing an antisense RNA to insulin-like growth factor I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994;54:2218-2222.
6. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994;54:4848-4850.
7. Prager D, Li HL, Asa S, Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA. 1994;91:2181-2185.
8. Miura M, Li S, Baserga R. Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. Cancer Res. 1995;55:663-667.
9. Burgaud JL, Resnikoff M, Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun. 1995;214:475-481.
10. Reiss K, D'Ambrosio C, Tu X, Tu C, Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 1998;4:2647-2655.
11. Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998;58:3353-3361.
12. Rininsland F, Johnson TR, Chernicky CL, et al. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA. 1997;94:5854-5859.
13. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray E, ed. Gene Transfer and Expression Protocols. Clifton, NJ: Humana Press; 1991:109-128.
14. Tang DC, Johnston SA, Carbone DP. Tumor-restricted gene expression by adenovirus-mediated gene transfer. Cancer Gene Ther. 1994;1:15-20.
15. Lee C-T, Wu S, Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 1996;56:3038-3041.
16. Becker TC, Noel RJ, Coats WS, et al. Use of recombination of adenovirus for metabolic engineering of mammalian cells. In: Roth MG, ed. Protein Expression in Animal Cells. New York: Academic Press; 1994:161-188.
17. Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene products. Cancer Res. 1996;56:3831-3836.
18. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1998;18:1595-1606.
19. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor-I. Mol Cell Biol. 1998;18:6711-6718.
20. Grimberg A, Cohen P. Growth hormone and prostate cancer: guilty by association? J Endocrinol Invest. 1999;22:64-73.
21. Ma J, Pollack MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999;91:620-625.
22. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case control analysis. J Natl Cancer Inst. 1999;91:151-156.
23. Scotland K, Benini S, Nani P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic nude mice. Cancer Res. 1999;58:4127-4131.
24. Trojan J, Blossey BK, Johnson TR, et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA. 1992;89:4874-4878.
25. Hongo A, Yumet G, Resnicoff M, Romano G, O'Connor R, Baserga R. Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristoylated COOH terminus of insulin-like growth factor I receptor. Cancer Res. 1998;58:2477-2484.
26. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
27. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
28. Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997;272:154-161.
29. Peruzzi F, Prisco M, Dews M, et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999;19:7203-7215.
30. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 1996;56:4013-4020.
31. Jiang Y, Rom WN, Yie T-A, Chi CX, Tchou-Wong K-M. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene. 1999;18:6071-6077.